Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AXIM Biotechnologies, Inc. (AXIM)
USD0.00
0.00 (-4.33%)
US OTC Healthcare Biotechnology
Address
6191 Cornerstone Court, East 92121
San Diego, CA, US
San Diego, CA, US
CEO
Catalina Valencia
Website
aximbiotech.com
IPO
2014-09-02
CIK 1514946 ISIN US05463V1008
Description
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
0.00 (-4.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
148.6K
Beta
-0.23
Float Shares
243.75M
Free Float %
71.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +13.64% | +13.21% | +9.09% | -45.95% | -70.66% | -43.93% | -12.41% | -72.67% | -99.19% | -98.67% | -99.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-35.89
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
4 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q2'25: -100.0% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+71.8% ★ Q2'25: +104.0% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'25: -30.5% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+6.8% Q2'25: +15.2% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-8.72× Q2'25: 5.74× (vs Q2'24)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.26M
OE per share TTM
0.00
Owner's Yield
-67.09%
Maintenance CapEx ratio
15.82%
Maint CapEx / Avg PPE
123.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sanammad Foundation | 22.71M | 43.00% | — | — | 22.71M | 10.00 | CO | The Netherlands | 2017-03-01 | ↗ |
| 2 | Medical Marijuana, Inc. | 22.67M | 43.00% | — | — | 22.67M | 10.00 | CO | Oregon | 2017-03-01 | ↗ |
| 3 | Schedule 13D | 500.0K | 4.00% | — | — | — | 10.00 | CO | — | 2022-09-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
13.22M
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+13,215,016
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | Valencia Catalina | 10% Owner | A-Award | A | Convertible Note | 7,837,500 | 0.02 | 156.8K | 7,837,500 | — | ↗ |
| 2024-03-15 | Scott Timothy Richard | Director | A-Award | A | Convertible Note | 35,000 | 0.01 | 350.00 | 4,500,000 | — | ↗ |
| 2024-03-15 | Schroeder Blake | Director | A-Award | A | Convertible Note | 35,000 | 0.01 | 350.00 | 4,500,000 | — | ↗ |
| 2024-03-15 | O'Rourke Peter | Director | A-Award | A | Convertible Note | 35,000 | 0.01 | 350.00 | 4,500,000 | — | ↗ |
| 2024-03-15 | MALASEK ROBERT | Officer | A-Award | A | Convertible Note | 53,500 | 0.02 | 1.1K | 3,475,000 | — | ↗ |
| 2024-03-15 | HUEMOELLER JOHN WALTER II | Director / Officer | A-Award | A | Convertible Note | 1 | 0.02 | 0.02 | 42,500,000 | — | ↗ |
| 2024-03-15 | Cunningham Robert L | Director | A-Award | A | Convertible Note | 35,000 | 0.01 | 350.00 | 4,500,000 | — | ↗ |
| 2024-01-30 | Valencia Catalina | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,086,216 | 0.00 | — | 28,608,220 | D | ↗ |
| 2023-05-23 | Phinney Kurt | Officer | — | I | Option | 2,000,000 | 0.02 | 40.0K | 0 | — | ↗ |
| 2022-09-23 | Scott Timothy Richard | Director | A-Award | A | Option | 1,000,000 | 0.05 | 52.0K | 1,500,000 | — | ↗ |
| 2022-09-23 | Schroeder Blake | Director | A-Award | A | Option | 1,000,000 | 0.05 | 52.0K | 1,000,000 | — | ↗ |
| 2022-09-23 | MALASEK ROBERT | Officer | A-Award | A | Option | 500,000 | 0.05 | 26.0K | 800,000 | — | ↗ |
| 2022-09-23 | HUEMOELLER JOHN WALTER II | Director / Officer | A-Award | A | Option | 5,000,000 | 0.05 | 260.0K | 8,000,000 | — | ↗ |
| 2022-09-23 | Cunningham Robert L | Director | A-Award | A | Option | 1,000,000 | 0.05 | 52.0K | 1,500,000 | — | ↗ |
| 2022-08-29 | Valencia Catalina | Director | P-Purchase | A | Common Stock | 3,861,004 | 0.03 | 100.0K | 23,661,004 | — | ↗ |
| 2022-08-22 | Schroeder Blake | Director | C-Conversion | A | Common Stock | 854,012 | 0.03 | 24.8K | 854,012 | — | ↗ |
| 2022-02-10 | Schroeder Blake | Director | J-Other | A | Convertible Note (Convertible into Common Stock) | 25,000 | 0.08 | 2.0K | 307,692 | — | ↗ |
| 2021-05-06 | HUEMOELLER JOHN WALTER II | Director / Officer | D-Return | D | Option | 2,000,000 | 0.75 | 1.50M | 3,000,000 | — | ↗ |
| 2020-12-10 | MALASEK ROBERT | Officer | A-Award | A | Option | 300,000 | 0.42 | 126.0K | 300,000 | — | ↗ |
| 2020-12-10 | HUEMOELLER JOHN WALTER II | Director / Officer | A-Award | A | Option | 3,000,000 | 0.42 | 1.26M | 5,000,000 | — | ↗ |
| 2020-05-13 | Scott Timothy Richard | Director | A-Award | A | Option | 500,000 | 0.01 | 6.3K | 500,000 | — | ↗ |
| 2020-05-13 | Cunningham Robert L | Director | A-Award | A | Option | 500,000 | 0.01 | 6.3K | 500,000 | — | ↗ |
| 2020-03-19 | Valencia Catalina | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 19,800,000 | — | ↗ |
| 2020-03-19 | HUEMOELLER JOHN WALTER II | Director / Officer | P-Purchase | A | Common Stock | 6,000,000 | 0.00 | — | 6,000,000 | — | ↗ |
| 2020-03-19 | Glycodots, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 19,800,000 | — | ↗ |
| 2019-01-02 | HUEMOELLER JOHN WALTER II | Director / Officer | A-Award | A | Option | 2,000,000 | 0.75 | 1.50M | 2,000,000 | — | ↗ |
| 2018-03-21 | MALASEK ROBERT | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2017-05-18 | Scott Timothy Richard | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-18 | Schroeder Blake | Director | — | D | Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-18 | HUEMOELLER JOHN WALTER II | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-18 | Cunningham Robert L | Director | — | D | Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-31 | Medical Marijuana Inc | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-31 | Changoer Lekhram | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-31 | Anastassov George | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-06-29 | MALASEK ROBERT | Officer | — | D | Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-02-05 | Anastassov George | Director / Officer / 10% Owner | A-Award | A | Common Stock | 125,000 | 0.00 | — | 15,365,650 | — | ↗ |
| 2015-12-18 | Changoer Lekhram | Director / 10% Owner | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2015-11-09 | Anastassov George | Director / Officer / 10% Owner | A-Award | A | Common Stock | 125,000 | 0.00 | — | 15,240,650 | — | ↗ |
| 2015-04-23 | Changoer Lekhram | Director / 10% Owner | A-Award | A | Preferred Stock | 1,000,000 | 0.00 | — | 1,500,000 | — | ↗ |
| 2015-04-23 | Anastassov George | Director / Officer / 10% Owner | A-Award | A | Preferred Stock | 1,000,000 | 0.00 | — | 1,500,000 | — | ↗ |
| 2015-02-23 | Anastassov George | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,000 | 0.00 | — | 14,945,650 | — | ↗ |
| 2014-03-21 | Van Damme Philip A | 10% Owner | — | I | Preferred Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2014-03-21 | Sanammad Foundation | 10% Owner | — | D | Preferred Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2014-03-21 | SAMUELS ROSEMARY | Director / Officer / 10% Owner | S-Sale | D | PREFERRED STOCK | 1,000,000 | 400.00 | 400.00M | 0 | — | ↗ |
| 2014-03-21 | Medical Marijuana, Inc. | 10% Owner | — | D | Preferred Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2014-03-21 | Changoer Lekhram | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 14,943,650 | — | ↗ |
| 2014-03-20 | Anastassov George | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 14,943,650 | — | ↗ |
| 2013-12-31 | SAMUELS ROSEMARY | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2012-12-31 | SAMUELS ROSEMARY | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2011-12-31 | SAMUELS ROSEMARY | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2011-07-12 | SAMUELS ROSEMARY | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 20,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
340.46M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Catalina Valencia | Chief Executive Officer, President & Director | 187.5K | female |
| Robert T. Malasek | Chief Financial Officer & Secretary | 90.0K | male |
| Jeffrey A. Busby | Head of Global Sales | — | male |
| Joseph Tauber | Chief Medical Officer & Chairman of the Medical Advisory Board | — | — |
| Kurt Phinney | Chief Operating Officer | — | male |
| Maria J. Gonzalez Moa | Vice President of Product Development - Sapphire Biotech, Inc. | — | — |
| Alim Seit-Nebi | Chief Technology Officer & Co-Founder of Sapphire Biotech, Inc. | — | — |
| Sergei A. Svarovsky | Chief Scientific Officer | — | — |
| Douglas Lake | Chief Clinical Officer of Sapphire Biotech, Inc. | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AXIM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
